

FORM PTO-1390 (Modified) (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 025098/2802
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/807355</b>
INTERNATIONAL APPLICATION NO. <b>PCT/US99/20971</b>	INTERNATIONAL FILING DATE <b>10 September 1999</b>	PRIORITY DATE CLAIMED <b>11 September 1998</b>		
<b>TITLE OF INVENTION</b> <b>REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES</b>				
<b>APPLICANT(S) FOR DO/EO/US</b> <b>Peter B. DERVAN</b>				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))  <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).  <input type="checkbox"/> has been transmitted by the International Bureau.  <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> An English translation of the International Application into English (35 U.S.C. 371(c)(2)).  <input type="checkbox"/> is attached hereto.  <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154 (d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).  <input type="checkbox"/> have been transmitted by the International Bureau.  <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.  <input type="checkbox"/> have been made and filed in the United States Receiving Office.</p> <p>8. <input type="checkbox"/> An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
Items 11 to 20 below concern other document(s) or information included:				
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items of information:</p>				

U.S. APPLICATION Unknown 09/807355		INTERNATIONAL APPLICATION NO. PCT/US99/20971		ATTORNEY'S DOCKET NUMBER 025098/2802	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee (37 CFR 1.492(a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 International preliminary examination fee paid (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 International preliminary examination fee paid (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO And all claims satisfied provisions of PCT Article 33 (1)-(4) ..... \$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b> \$860.00					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	24	-	20	= 4	\$18.00
Independent Claims	1	-	3	= 0	\$80.00
Multiple dependent claim(s) (if applicable)				\$270.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b> \$932.00					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					
<b>SUBTOTAL =</b> \$466.00					
Processing fee of \$130.00 for furnishing English translation later the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f). +					
<b>TOTAL NATIONAL FEE =</b> \$0.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
<b>TOTAL FEES ENCLOSED =</b> \$466.00					
Amount to be refunded: charged:					
a. <input checked="" type="checkbox"/> A check in the amount of \$609.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-0872</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: Foley & Lardner 402 W. Broadway, Suite 2300 San Diego, California 92101-3542 Telephone: (310) 975-7963					
 SIGNATURE NAME MICHAEL A. WHITTAKER REGISTRATION NUMBER 46,230					

472

**PETITION FOR REVIVAL OF AN INTERNATIONAL  
APPLICATION FOR PATENT DESIGNATING THE U.S.  
ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number (Optional)

**025098/2802**First Named Inventor: **DERVAN, Peter B.**International (PCT) **PCT/US99/20971** U.S. Application No. **Unknown**  
Application No. **(if known)**Filed: **10 September 1999**Title: **REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC  
POLYAMIDES****RECEIVED**Attention: PCT Legal Staff  
Box PCT  
Assistant Commissioner for Patents  
Washington, DC 20231**26 APR 2001****Legal Staff  
International Division**

The above identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.494(b) or (c) or 1.495(b) or (c) (as applicable). The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.494(g) or (h).

**APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION**

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee – required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

**1. Petition Fee**

- Small entity – fee \$620 (37 CFR 1.17(m)) Applicant claims small entity status.  
See 37 CFR 1.27
- Other than small entity – fee \$1,240 (37 CFR 1.17(m))

**2. Proper Reply**

- A. The proper reply (the missing 35 U.S.C. 371(c) requirements) in the form of:

the national filing fee (identify type of reply):

- has been provided \_\_\_\_\_  
 is enclosed herewith.

**3. Terminal disclaimer with disclaimer fee**


Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.

A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$55.00 for a small entity or \$110.00 for other than a small entity) equivalent to the period of abandonment is enclosed herewith (see PTO/SB/63).

**4. Statement**

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

Dated: April 10, 2001

  
Michael A. Whittaker, Reg. No. 46,230

Agent for Applicant

FOLEY & LARDNER

402 W. Broadway, Suite 2300

San Diego, California 92101-3542

+1-619-234-6655 Office

+1-619-234-3510 Fax

Enclosures:  Response  
 Fee Payment  
 Terminal Disclaimer Form

5'-CCCGGGGTCTGGAAGCCACAAGGTAAACACAACACATCCCCCTCCTGACTATGCAATTACTA  
 GAGGATGTGGTGGAAAACCATTATTGATATTAAAACAAATAGGCTTGGATGGAGTAGGATGCAAGCT  
 CCCCAGGAAAGTTAAGATAAAACCTGAGACTTAAAGGGTGTAAAGAGTGGCAGCCTAGGGAATTATC  
 CGGACTCCGGGGAGGGGCAGAGTCACCAGCCTGCATTAGGGATTCTCGAGGAAAAGTGTGAGA  
**AP-2**  
ACGGCTGCAGGCAACCCAGGCGTCCGGCGTAGGAGGGACGACCCAGGCTGCGGAAGAGAGGGAGAA  
 AGTGAAGCTGGAGTTGCCGACTCCCAGACTTCGTTGAATGCAGTTGGAGGGGCGAGCTGGAGCGCG  
**CCAAT box** **Ets TATA**  
CTTGCTCCCAATCACAGGAGAAGGAGGAGGTGGAGGAGGGCTGCTTGAAGTATAAGAATGAAGT  
 TGTGAAGCTGAGATTCCCTCCATTGGGACCGGAGAAACCAGGGAGGCCCCCGGGCAGCCGCGCCCC  
**A+1**  
 TTCCCACGGGCCCTTACTGCGCCGCGCCGGCCCCACC-3'


#### HER2/neu Promoter Elements

TATA: TBP/TFIID

Ets: ESX, perhaps also PEA3, ERM

CCAAT box: NF-Y (also called CP1, CBF, EFL)

**Fig. 1A**



**Fig. 1B**




Fig. 2A







Fig. 2B



70



86

**Fig. 3**





Fig. 4

09/807355

WO 00/15242

PCT/US99/20971



**Fig. 5**

09/807355  
PCT/US99/20971

WO 00/15242




Fig. 6

09/807355

Rec'd PCT/PTO 10 APR 2001  
PCT/US99/20971

WO 00/15242

1

**REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC  
POLYAMIDES**

5 The U.S. Government has certain rights in this invention pursuant to Grant Nos. GM 26453, 27681 and AI 29182 awarded by the National Institutes of Health.

**RELATED APPLICATIONS**

This application claims benefit of priority from U.S. Provisional Application 10 60/099,906, filed September 11, 1998, which is hereby incorporated by reference as if fully set forth.

**FIELD OF THE INVENTION**

This invention is directed generally to methods and compositions for the 15 modulation, or regulation, of gene expression by the use of polyamides that bind DNA. The methods and compositions result in inhibition, or down-regulation, of gene expression or overexpression by interactions between the polyamides and the minor groove of double-stranded DNA (dsDNA). The polyamides of these methods and compositions bind predetermined target nucleic acid sequences located within the 20 promoter region of genes to be down-regulated or inhibited. Inhibition or down-regulation of target oncogenes that are expressed, or overexpressed, at undesirable levels is one application of the invention. In particular, the invention is directed to reducing the expression or overexpression of target endogenous cellular oncogenes.

25 **BACKGROUND OF THE INVENTION**

The tyrosine kinase membrane growth factor receptor HER2/neu, also known as p185<sup>HER2</sup>, is encoded by a cellular oncogene of the same name that is overexpressed and amplified in 20 to 30% of human breast cancers, among others, including other 30 human gynecologic adenocarcinomas, such as those of the ovary, endometrium, fallopian tube, and cervix.. See Baert, J.-L. et al., *Int. J. Cancer* 70, 590-597 (1997); Benz, C., et

al., *Oncogene* **15**, 1513-1525 (1997); Chang, C.-H., et al., *Oncogene* **14**, 1617-1622 (1997); Scott, G. K., et al., *J. Biol. Chem.* **269**, 19848-19858 (1994); Pasleau, F.; et al., *Oncogene* **8**, 849-854 (1993); Tal, M. et al., *Molecular and Cellular Biology* **7**, 2597-2601 (1987); (Cirisano, F.D., & Karlan, B.Y., *J. Soc. Gynecol. Investig.* **3** 99-105 (1996)).

5       The neu oncogene gene product was originally described in chemically-induced (ethylnitrosourea) tumors in rodents. Subsequently, the human counterpart, c-erbB-2 or Her-2/neu, was found to be homologous to the EGF receptor, a 185 kDa transmembrane protein with protein tyrosine kinase activity. Overexpression of HER2/neu is also associated with the likelihood that tumors will metastasize, with a resulting poor  
10      prognosis for the patient. Mutation, amplification, and overexpression of the Her-2/neu oncogene has been reported to be associated with breast tumor progression, early metastasis and poor prognosis. Her-2/neu gene amplification directly correlates with lymph node metastasis. Additionally, in an animal model, activating mutations lead to rapid tumor progression. As a result, it is believed that the Her-2/neu protein likely plays  
15      a role in cell motility and hence in metastasis. Thus, inhibition of Her-2/neu gene expression by direct interference at the DNA level may be a potent therapeutic approach for metastatic disease.

Several transcription factors - such as ESX, AP-2, and the TATA binding protein ("TBP") - play an important role in the regulation of the expression of the gene for the  
20      HER2/neu growth factor receptor. See Baert, J.-L. et al., Benz, C., et al; supra; Chang, C.-H., et al., supra; Bosher, J. M., et al., *Proc. Natl. Acad. Sci. USA* **92**, 744-747 (1995). These transcription factors activate the expression of p185<sup>HER2</sup> upon binding to sites within the HER2/neu promoter. The nucleotide sequence of the HER2/neu promoter and a schematic representation are shown in Figure 1.

25      TBP is ubiquitous transcription factor that is involved in the activation of most protein-encoding genes. TBP is a DNA-binding protein that interacts to the minor groove of DNA. It should be noted that, apart from ESX, AP-2, and TBP, there are other potential transcription factor binding sites within the HER2/neu promoter.

30      Considerable effort has been expended in the art to devise methods to interfere with gene expression in living cells in the hope that therapeutic strategies will come from

these studies. These approaches include interference with the translation of messenger RNA into protein by the introduction of antisense oligonucleotides into cells (natural or peptide nucleic acid based) or by ribozyme-mediated destruction of specific RNAs. Several approaches for direct inhibition of gene transcription have also been attempted; 5 these include triple helix forming oligonucleotides, designed or selected zinc finger peptides that recognize pre-determined sequences, and DNA-binding calicheamicin oligosaccharides.

For any therapeutic approach based in interference with gene expression to be successful, several criteria must be met by the therapeutic agent: first, the agent must not possess any general cell toxicity; second, the agent must be cell-permeable and, in the case of the DNA-binding agents, the compounds must transit to the nucleus and bind their target sequence with high affinity and specificity in the context of cellular chromatin; and, third, binding of the agent to its DNA target sequence must interfere with gene transcription. Each of the potential approaches listed above has its own peculiar 10 limitations. For example, while triple helix-forming oligonucleotides have the potential for sequence selectivity and can effectively inhibit transcription *in vitro*, these molecules suffer from poor cell permeability and permeabilized cells need to be used for effective gene inhibition. Similarly, zinc finger peptides must be introduced via a gene therapy approach with an appropriate viral or non-viral expression vector since these peptides 15 cannot directly enter cells. In contrast, the calicheamicin oligosaccharides are sufficiently hydrophobic to pass through cell membranes, but these molecules possess severely limited sequence specificity (4 bp) and bind DNA with very low affinities (100 µM or higher required for inhibition of protein-DNA interactions). Thus, new classes of cell-permeable molecules that possess higher degrees of DNA sequence specificity and 20 affinity are needed for any human gene therapeutic approach to be feasible.

Another approach utilizes cell-permeable small molecules that target particular DNA sequences. These molecules would be useful for the regulation of gene expression. The design of small synthetic DNA-binding ligands that recognize specific sequences in the DNA double helix has been a long standing goal of chemistry. 30 Oligodeoxynucleotides that recognize the major groove of double-helical DNA via triple-

helix formation bind to a broad range of sequences with high affinity and specificity. Although oligonucleotides and their analogs have been shown to interfere with gene expression, the triple helix approach is limited to purine tracks and suffers from poor cellular uptake.

5 Other small molecules have also been of interest as DNA-binding ligands. Wade, et al. reported the design of peptides that bind in the minor groove of DNA at 5'-(A,T)G(A,T)C(A,T)-3' sequences by a dimeric side-by-side motif (*J. Am. Chem. Soc.* **114**, 8783-8794 (1992)). Mrksich, et al. reported antiparallel side-by-side motif for sequence specific-recognition in the minor groove of DNA by the designed peptide 1-methylimidazole-2-carboxamidene tropsin (*Proc. Natl. Acad. Sci. USA* **89**, 7586-7590 (1992)). Pelton, J.G. & Wemmer, D.E. reported the structural characterization of a 2-1 distamycin A-d(CGCAAATTGGC) complex by two-dimensional NMR (*Proc. Natl. Acad. Sci. USA* **86**, 5723-5727 (1989)).

10 Dervan and colleagues have shown that synthetic pyrrole-imidazole polyamides bind DNA with excellent specificity and very high affinities, even exceeding the affinities of many sequence-specific transcription factors (Trauger, et al., *Nature* **382**, 559-561 (1996)). They further describe the recognition of DNA by designed ligands at subnanomolar concentrations. DNA recognition depends on side-by-side amino acid pairing of imidazole-pyrrole or pyrrole-pyrrole pairs in the minor groove. White, S., et 15 al., (1996) reported the effects of the A•T/T•A degeneracy of pyrrole-imidazole polyamide recognition in the minor groove of DNA (*Biochemistry* **35**, 6147-6152 (1996)). White, et al. (1997) reported pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides (*Chem. & Biol.* **4**, 569-578 (1997)), and demonstrated the 5'-3' N-C orientation preference for polyamide binding in the minor 20 groove. Thus, polyamide molecules thus have the potential to act as inhibitors of protein-DNA interactions in the minor groove.

25 The development of pairing rules for minor groove binding polyamides derived from N-methylpyrrole (Py) and N-methylimidazole (Im) amino acids provides another means to confer sequence specificity. An Im/Py pair distinguishes G•C from C•G, and both of these from A•T or T•A base pairs, while Py/Im targets a C-G basepair. A Py/Py

pair specifies A•T from G•C but does not distinguish A•T from T•A. The generality of this approach to the rational design of sequence-specific DNA ligands is supported by direct NMR structural studies (Geierstanger, et al., *Science* 266,646-650 (1994)) and the recent success in synthesis of an eight ring hairpin polyamide which targets a six base pair sequence with an apparent dissociation constant of 0.03 nM (Trauger, et al., above). Moreover, two eight-ring pyrrole-imidazole polyamides differing in sequence by a single amino acid residue bind specifically to respective six base-pair target sites that differ in sequence by a single base pair. The replacement of a single nitrogen atom with a C-H can regulate specificity and affinity by two orders of magnitude.

Since a six base-pair sequence would be highly redundant in the human genome (occurring at random once every 4 kilobases, or 500,000 times in the human genome), polyamides have been synthesized to recognize much longer sequences. For example, a twelve-ring double hairpin polyamide has been designed to target a 12 bp site and binding is again observed with nanomolar affinity. Such a sequence would be predicted to occur at random only once every 16 million base pairs, or only 125 times in the human genome. Such molecules thus have the potential to act as specific inhibitors of gene transcription *in vivo* and as human therapeutic agents if the conditions outlined above can be met.

20 **SUMMARY OF THE INVENTION**

The present invention relates to and includes methods and compositions for the modulation, or regulation, of gene expression or overexpression by reducing the transcription of genes. Preferably, the transcription of specific individual target genes is reduced. Such reductions result from the application of polyamides that bind or interact with the minor groove of double-stranded DNA (dsDNA) within the promoter regions of target genes. Preferably, the binding or interaction is with a predetermined target nucleic acid sequence within the promoter regions to inhibit or down-regulate transcription.

The present invention reduces gene expression and overexpression by use of sequence-specific DNA-binding small molecules that are cell-permeable and capable of inhibiting gene transcription. Appropriate application of such molecules may inhibit

overexpression of endogenous oncogenes to provide a fundamentally new therapeutic strategy for the treatment of various diseases, including cancer. The small molecules of the invention are polyamides that bind to or interact with nucleic acid sequences within the promoter region of target genes. Preferably, these sequences are recognized, or 5 proximal to those that are recognized, by one or more transcription factors.

Preferably, the polyamides bind to the minor groove of double-stranded DNA in a promoter region that controls the transcription and expression of a gene. Preferably the transcription of the gene is inhibited by modulating the binding of a protein transcription factor to dsDNA. In preferred embodiments, the transcription factors are ESX, ETS, and 10 TBP.

Previous studies directed toward inhibition of the transcriptional activity of the HIV-1 promoter have demonstrated that polyamides can block binding of TBP as well as an *Ets* family transcription factor (see PCT published application PCT/US98/02444, now WO 98/35702, the teachings of which are incorporated by reference as if fully set forth). 15 In principle, both classes of transcription factors can be inhibited by polyamides that contact or bind the minor groove of dsDNA. DNA complexation of proteins contacting the minor groove may be inhibited by direct steric hinderance, repulsion, or exclusion or, alternatively, byallosteric efforts. For example, the binding of major groove binding proteins may be suppressed by a polyamide-induced change of the DNA conformation. 20 Of course, inhibition can also be achieved other ways, for example, by conjugating a DNA cleavage agent to a polyamide targeted to a desired site, or by chemically modifying DNA.

In one preferred aspect of the invention, the expression or overexpression of oncogenes is targeted. Preferably, the oncogenes are endogenous cellular oncogenes 25 involved in cancer, particularly human breast cancer. One oncogene target of the invention is the HER-2/neu gene, which may be down-regulated or inhibited by the use of polyamides that bind to target sequences within the HER-2/neu promoter region. Preferably, these sequences are, or are proximal to, transcription factor binding sites within the HER2/neu promoter. Interactions or binding between the polyamide and the 30 target sequence can inhibit the transcription of the HER2/neu gene. The degree of

inhibition of HER2/neu expression may be extensive and includes the inhibition of HER2/neu overexpression. The invention further encompasses application of polyamides for the treatment of various tumors or cancers, including breast cancer.

Suitable polyamides have a binding affinity at the dsDNA target sequence of at least  $10^9 \text{ M}^{-1}$  and a selectivity of at least about two. Selectivity is defined as the ratio of the binding affinity for the identified dsDNA target sequence to the binding affinity for a single base-pair mismatch dsDNA sequence. In preferred embodiments, selectivity against at least 90% of single base mismatch sequences is greater than about 10.

In a related aspect of the present invention, compositions are provided that comprise a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide of the invention. Each polyamide contains at least four complementary pairs of aromatic carboxamide residues, which pairs are selected to correspond to an identified nucleotide sequence of a dsDNA target. Preferably, the polyamides additionally comprise at least two aliphatic amino acid residues chosen from the group consisting of glycine,  $\beta$ -alanine,  $\gamma$ -aminobutyric acid, R-2,4-diaminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue, the polyamide having a binding affinity at the target dsDNA sequence of at least  $10^9 \text{ M}^{-1}$  and a selectivity of at least about two, selectivity being defined as the ratio of the binding affinity for the identified target dsDNA sequence to the binding affinity for a single base-pair mismatch dsDNA sequence.

The invention further provides methods suitable for treating a subject having a condition associated with abnormal expression of a cellular oncogene. The subject is preferably a human patient and, more particularly, one afflicted with breast cancer or other diseases or conditions associated with aberrant Her-2/neu oncogene expression.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the HER2/neu promoter, showing the nucleotide sequence in A, including binding sites of Ets, AP-2, and TBP ("TATA") transcription factors and the "CCAAT box", and in B, a schematic diagram, not to scale.

Figure 2A is a graphical representation of the results of a DNase I footprint titration of polyamide **HER2-1** (left) and the mismatch polyamide ImPy- $\beta$ -PyIm- $\gamma$ -PyPyPyPyPy- $\beta$ -Dp (right) and 2B, the schematic structures and association constants of 5 the polyamides, where the polyamides are represented by closed circles for imidazole rings, open circles for pyrrole rings, curved lines for  $\gamma$ -aminobutyric acid, diamonds for  $\beta$ -alanine, and a half circle with a positive charge for dimethylaminopropylamide.

Figure 3 compares the sequence of the HER2/neu promoter and polyamide 10 structures and binding sites; the binding site for the TATA binding protein (TBP) is indicated along with the structures of the polyamides HER2-A, HER2-1, 70, and the mismatch polyamide 86.

Figure 4 is a graphical representation of the results of experiments showing the 15 effects of polyamides Her2-1 (A) and **70** on TBP binding.

Figure 5 is a graphical representation of the results of experiments showing the 20 effects of the polyamide HER2-1 on HER2/neu transcription *in vitro* in a cell free system.

Figure 6 is a graphical representation of the results of experiments showing the effects of the polyamides HER2-1 and **70** on HER2/neu mRNA production in the human breast cancer cell line SK-BR-2.

25 **DETAILED DESCRIPTION**

The present invention is directed to methods and compositions for modulating or regulating gene expression or overexpression by reducing gene transcription. The methods and compositions are preferably directed toward the inhibition of oncogene transcription, especially of oncogenes involved in cancer, particularly human cancer and especially breast 30 cancer.

The reductions in gene transcription result from binding or other interactions between polyamides and the minor groove of dsDNA within the promoter regions of target genes. Preferably, the polyamides bind or interact with specific target nucleic acid sequences within the promoter regions to inhibit or down-regulate transcription. Preferably, 5 the sequences are recognized, or proximal to those that are recognized, by one or more transcription factors.

The polyamides are preferably cell-permeable and capable of inhibiting gene transcription *in vivo*, *in vitro*, or in cell free systems. Appropriate application of such polyamide molecules may be used to inhibit expression or overexpression of endogenous 10 oncogenes as a treatment of various diseases, including cancer.

In preferred embodiments, the polyamides bind to the minor groove of double stranded DNA in a promoter region that controls the transcription and expression of a target gene. Preferred target genes are endogenous oncogenes involved in cancer formation or progression. Preferably the transcription of the gene is inhibited by 15 modulating the binding of a protein, such a transcription factor, to the same promoter region with which the polyamide binds or interacts. In especially preferred embodiments, the transcription factors are one or more of the following: ESX; ETS; and TBP.

Inhibition of transcriptional activity at the HIV-1 promoter demonstrates that polyamides can block binding of TBP as well as an *Ets* family transcription factor See 20 WO 98/35702, which includes a discussion of polyamide synthesis. The present invention includes the use of polyamides that inhibit or modulate the activity of both TBP and *Ets* transcription factors. The invention may affect transcription factor activity by use 25 of one or more polyamides that contact or bind the minor groove of dsDNA. Such contact or binding may inhibit formation of DNA-transcription factor complexes in the minor groove by direct steric repulsion, allosteric effects, or other mechanisms (e.g., cleavage or chemical modification of the dsDNA). This is possibly in contrast to major groove DNA binding proteins, such as TBP, which may be inhibited by a polyamide-induced change in DNA conformation.

In a preferred aspect of the invention, the expression or overexpression of 30 oncogenes, especially endogenous cellular oncogenes, is targeted. Preferably, the

oncogenes are those implicated in human breast cancer, and their expression or overexpression is inhibited by polyamides that contact or bind the minor groove in the region of the oncogene promoter. Preferably, the contacted or bound portions of the promoter region are, or are proximal to, transcription factor binding sites. The degree of inhibition is preferably large and more preferably enough to inhibit even overexpression of the oncogene, in when the copy number of the gene increases.

One oncogene target of the invention is the HER-2/neu gene, which may be down-regulated or inhibited by the use of polyamides that bind to target sequences within the HER-2/neu promoter region. Preferably, these sequences are, or are proximal to, transcription factor binding sites within the HER2/neu promoter. These transcription factors include TBP, ESX and AP-2. Interactions or binding between the polyamide and the target sequence result in inhibition of the HER2/neu gene transcription.

In a preferred embodiment, a polyamide was designed to bind immediately downstream of the TATA element found in the human Her-2/neu breast cancer oncogene promoter. This polyamide, Her2-1, of composition ImPy- $\beta$ -PyIm- $\gamma$ -PyPy- $\beta$ -PyPy- $\beta$ -Dp, binds the sequence 5'-AGAATGA-3' (where the 5' A of this sequence is the 3' A of the TATA element) with an apparent dissociation constant of 200 pM. Her2-1 is an effective inhibitor of TBP binding and transcription.

The present invention includes compositions comprising a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide for the inhibition of gene expression or overexpression. These compositions may also be used for the treatment of various tumors or cancers, including breast cancer. The invention further provides methods of administering such compositions to result in inhibition of gene expression or overexpression. The methods and compositions are preferably suited for treating a subject having a condition associated with abnormal expression of a cellular oncogene. The subject is preferably a human patient particularly one afflicted with cancer, especially breast cancer.

Polyamides of the invention

The polyamides used in the present invention comprise N-methylimidazole and N-methylpyrrole carboxamides. These polyamides generally have a crescent-shaped structure that permits interaction and complexation the minor groove of double-stranded DNA. NMR studies have confirmed that these compounds can bind to DNA in a 2:1 ratio by a motif in which two polyamide ligands are arranged in an antiparallel way, side-by-side to each other (Pelton, J., et al., *Proc. Natl. Acad. Sci. USA* **86**, 5723-5727 (1986); Mrksich, M., et al., *Proc. Natl. Acad. Sci. USA*, **89**, 7586-7590 (1992); Wade, W. S., et al., *J. Am. Chem. Soc.* **114**, 8783 (1992)).

One means to increase the binding affinity of two polyamides is to covalently linked them with a turn-unit such as  $\gamma$ -aminobutyric acid (see Mrksich, M., et al., *J. Am. Chem. Soc.* **116**, 7983 (1994)). Such polyamides are called "hairpin polyamides", as they adopt a hairpin-like conformation in the DNA complex. The sequence of the imidazole and the pyrrole carboxamides in the polyamide determines the DNA sequence specificity of the ligand, according to the scheme of carboxamide pairs that recognize nucleotide pairs described above. In some cases it has been useful to replace one or several pyrrole carboxamide units with  $\beta$ -alanine moieties in order to adjust the curvature of the polyamide to that of the DNA. It has recently been shown that polyamides comprising N-methylimidazole and N-methylpyrrole carboxamides can inhibit gene expression in eukaryotic cells (Gottesfeld, J.M., et al. *Nature* **387**, 203-205 (1997)).

It has been found that polyamides containing a new aromatic amino acid, 3-hydroxy-N-methylpyrrole (Hp), paired opposite Py, have the ability to discriminate A•T nucleotide pairs from T•A nucleotide pairs in DNA sequences. The replacement of a single hydrogen atom on the pyrrole with a hydroxyl group in a Hp/Py pairing affects the affinity and specificity of a polyamide by an order of magnitude. By using Hp together with Py and Im in four pairs of aromatic amino acid residue combinations (Im/Py, Py/Im, Hp/Py, and Py/Hp), polyamides can selectively distinguish all four Watson-Crick base pairs in the minor groove of double stranded DNA. White, et al., *Nature* **391**, 468-471 (1998).

The invention encompasses the use of improved polyamides for binding to the minor groove of DNA in methods and compositions for reducing gene expression or overexpression. The preparation and use of polyamides for binding in the minor groove of DNA are described in the art. Included in the invention is an improvement of the existing technology which utilizes 3-hydroxy-N-methylpyrrole to provide carboxamide binding pairs for DNA binding polyamides. The improvement relates to the inclusion of a binding pair of Hp/Py carboxamides in the polyamide to bind to a T•A base pair in the minor groove of DNA or Py/Hp carboxamide binding pair in the polyamide to bind to an A•T base pair in the minor groove of DNA. The polyamides used in the invention have at least four carboxamide binding pairs that will distinguish A•T, T•A, C•G, and G•C base pairs in the minor groove. The polyamides may also have  $\gamma$ -aminobutyric acid or another turn unit to form a hairpin-loop with a member of each carboxamide pairing on each side of it.

The invention also includes polyamides containing a  $\beta$ -alanine substituted for a Py residue that would ordinarily be used in a carboxamide binding pair to match a particular nucleotide pair. The  $\beta$ -alanine is referred to in formulas of this invention as  $\beta$ . The  $\beta$ -alanine becomes a member of a carboxamide binding pair, and serves to optimize hydrogen bonding of neighboring amino acid moieties to nucleotide base pairs. The invention further includes the substitution of a  $\beta$ • $\beta$  binding pair for a non-Hp containing binding pair. Thus, binding pairs in addition to the Hp/Py and Py/Hp are Py/Py, Im/Py, Py/Im, Im/ $\beta$ ,  $\beta$ /Im, Py/ $\beta$ ,  $\beta$ /Py, and  $\beta$ / $\beta$ .

In general, the polyamides of the invention are suitable for inhibiting the transcription of a gene, preferably an oncogene. The polyamides consist of at least four complementary pairs of aromatic carboxamide residues, which pairs are selected to correspond to the nucleotide sequence of a dsDNA target. These polyamides contain at least two aliphatic amino acid residues chosen from the group consisting of glycine,  $\beta$ -alanine,  $\gamma$ -aminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue. The complementary pairs of aromatic carboxamide residues selected to correspond to the nucleotide sequence of an identified dsDNA target are chosen from the group consisting of Im/Py to correspond to the nucleotide pair G/C, Py/Im to

correspond to the nucleotide pair C/G, Py/Py to correspond to the nucleotide pair A/T, Py/Py to correspond to the nucleotide pair T/A, Hp/Py to correspond to the nucleotide pair T/A, and Py/Hp to correspond to the nucleotide pair A/T, where Im is N-methyl imidazole, Py is N-methyl pyrrole and Hp is 3-hydroxy N-methyl pyrrole. Application of  
5 the above principles permits the design of specific polyamides that bind or interact with specific target nucleic acid sequences for use in reducing gene expression or overexpression.

Preferred polyamides contain at least one  $\beta$ -alanine as an aliphatic amino acid residue. In preferred embodiments the terminal alkylamino residue is a N,N-dimethylaminopropyl residue. Suitable polyamides containing at least two  $\beta$ -alanine residues aligned to form complementary paired residues corresponding to a nucleotide pair chosen from the group A/T and T/A. Alternatively, corresponding pairs can be formed between aliphatic amino acids and aromatic carboxamides, such as Im/ $\beta$ ,  $\beta$ /Im, Py/ $\beta$  and  $\beta$ /Py. In preferred polyamides, a hairpin molecule is formed by inclusion an aliphatic amino acid residue such as  $\gamma$ -aminobutyric acid. Additionally, in some polyamides of the invention, at least one Py of a carboxamide pair is replaced by a  $\beta$ -alanine.  
10  
15

Suitable polyamides have a binding affinity at the dsDNA target sequence of at least  $10^9$  M<sup>-1</sup> and a selectivity of at least about two. Selectivity is defined as the ratio of  
20 the binding affinity for the identified dsDNA target sequence to the binding affinity for a single base-pair mismatch dsDNA sequence. In preferred embodiments, selectivity against at least 90% of single base mismatch sequences is greater than about 10.

Each polyamide used in the compositions of the invention preferably contains at least four complementary pairs of aromatic carboxamide residues, which pairs are selected to correspond to an identified nucleotide sequence of a dsDNA target. The polyamides also preferably contain at least two aliphatic amino acid residues chosen from the group consisting of glycine,  $\beta$ -alanine,  $\gamma$ -aminobutyric acid, R-2,4-diaminobutyric acid, and 5-aminovaleric acid, and at least one terminal alkylamino residue. The polyamides also preferably have a binding affinity at the target dsDNA sequence of at  
25  
30 least  $10^9$  M<sup>-1</sup> and a selectivity of at least about two, selectivity being defined as the ratio

of the binding affinity for the identified target dsDNA sequence to the binding affinity for a single base-pair mismatch dsDNA sequence.

Polyamide Her2-1 was designed to bind to the DNA sequence 5'-AGAATGA-3', which, as discussed above, is immediately adjacent to the TATA box of the HER2/neu promoter. DNase 1 footprint analysis confirms that this polyamide binds to the desired sequence with a dissociation constant ( $K_d$ ) of about 0.2 nM. Polyamide 70 also binds adjacent to, and partially overlaps, the HER2/neu TATA box. These polyamides targeted to the DNA sequences flanking or overlapping the Her-2/neu TATA element were synthesized by solid phase methods.

Polyamide Her2-A, of sequence composition ImIm- $\beta$ -PyIm- $\gamma$ -PyPy- $\beta$ -PyPy- $\beta$ -Dp (where Im represents imidazole, Py represents pyrrole,  $\gamma$  represents  $\gamma$ -aminobutyric acid,  $\beta$  represents  $\beta$ -alanine, and Dp represents dimethylaminopropylamide), binds the sequence 5'-AGGAAGT-3' at the 5' boundary of the Her-2/neu TATA element while polyamide Her2-1, of sequence composition ImPy- $\beta$ -PyIm- $\gamma$ -PyPy- $\beta$ -PyPy- $\beta$ -Dp, binds the sequence 5'-AGAATGA-3' at the 3' boundary of the TATA element (see Figure 1).

A mismatch polyamide of sequence composition ImIm- $\beta$ -ImIm- $\gamma$ -PyPy- $\beta$ -PyPy- $\beta$ -Dp (termed HIV-1) was also used in these studies. Polyamide 70, of sequence composition ImPyPyPy- $\gamma$ -PyPyPyPy- $\beta$ -Dp, binds the sequence 5'-AGTATA-3' overlapping the TATA box, while polyamide 86, of sequence composition ImPyImPy- $\gamma$ -PyPyPyPy- $\beta$ -Dp, is a mismatch polyamide, with a single atom substitution from polyamide 70.

Figure 1 shows the sequence of the Her-2/neu promoter region and the binding sites of several transcription factors. The hairpin polyamide ImPy- $\beta$ -PyIm- $\gamma$ -PyPy- $\beta$ -PyPy- $\beta$ -Dp was synthesized to bind immediately downstream of the TBP binding site (Figure 2B, left).

Quantitative DNase I footprinting experiments (Figure 2A) conducted on a  $^{32}$ P-end-labeled restriction fragment isolated from a HER2/neu gene-containing plasmid (Ebbinghaus, et al. "Triplex formation inhibits HER-2/neu transcription in vitro." J. Clin Invest. 92:2433-2439 (1993)) revealed that this polyamide (Her2-1) binds its target sequence with an equilibrium association constant of  $5 \times 10^9 \text{ M}^{-1}$ . The mismatch

polyamide ImPy- $\beta$ -PyIm- $\gamma$ -PyPyPyPy- $\beta$ -Dp (polyamide 70) bound the same sequence with an equilibrium association constant of  $2 \times 10^8 \text{ M}^{-1}$  (Figure 2B, right). The footprinting experiments indicated that this polyamide also binds the 5'-AGGAAGT-3' single-base pair mismatch sequence proximal to the ESX binding site with comparable affinity.

The TATA box region and binding models for each of these polyamides are shown in Figure 3. In this figure, polyamides are represented schematically between the two DNA strands at their respective binding sites. Shaded and unshaded circles represent imidazole (Im) and pyrrole (Py) rings, respectively; curved lines represent  $\gamma$ -aminobutyric acid ( $\gamma$ ); diamonds represent  $\beta$ -alanine ( $\beta$ ); and Dp represents dimethylaminopropylamide. The apparent binding affinities for each of these polyamides was determined by quantitative DNase I footprint titrations. Polyamide Her2-A binds its match site with a  $K_a$  of  $<10^8 \text{ M}^{-1}$  while polyamide Her2-1 binds with a  $K_a$  of  $5 \times 10^9 \text{ M}^{-1}$ . Given the higher affinity of Her2-1 for its target site, most of the examples described below utilized this compound. The binding constant for polyamide 70 has been reported previously (polyamide 2 in Trauger,*et al.*, *Nature* **382**, 559-561, 1996) and corresponds to  $3.5 \times 10^9 \text{ M}^{-1}$ . The mismatch polyamides bind with greatly reduced affinity.

#### Pharmaceutical and therapeutic compositions

The polyamides of the invention, as well as the pharmaceutically acceptable salts thereof, may be formulated into pharmaceutical or therapeutic compositions, formulations, or preparations. Pharmaceutically acceptable salts of the polyamide compounds of the invention are formed where appropriate with strong or moderately strong, non-toxic, organic, or inorganic acids or bases by methods known in the art. Exemplary of the salts that are included in this invention are maleate, fumarate, lactate, oxalate, methanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, citrate, hydrochloride, hydrobromide, sulfate, phosphate, and nitrate salts.

As stated above, the polyamide compounds of the invention possess the ability to inhibit gene expression or overexpression, properties that are exploited in the treatment of any of a number of diseases or conditions, most notably cancer and especially breast

cancer. A composition of this invention may be active *per se*, or may act as a "pro-drug" that is converted *in vivo* to an active form.

The compounds of the invention, as well as the pharmaceutically acceptable salts thereof, may be incorporated into convenient dosage forms, such as capsules, 5 impregnated wafers, tablets, or injectable preparations. Solid or liquid pharmaceutically acceptable carriers may be employed. Pharmaceutical compositions designed for timed release may also be formulated.

Preferably, the compounds of the invention are administered systemically, *e.g.*, by injection. When used, injection may be by any known route, preferably intravenous, 10 subcutaneous, intramuscular, intracranial, or intraperitoneal. Injectables can be prepared in conventional forms, either as solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Liquid carriers 15 include syrup, peanut oil, olive oil, saline, water, dextrose, glycerol and the like.

Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, liquid containing capsule, sterile injectable liquid (*e.g.*, a solution), such as an 20 ampoule, or an aqueous or nonaqueous liquid suspension. A summary of such pharmaceutical compositions may be found, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton Pennsylvania (Gennaro 18th ed. 1990).

The pharmaceutical preparations are made following conventional techniques of pharmaceutical chemistry involving such steps as mixing, granulating and compressing, 25 when necessary for tablet forms, or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral or parenteral, including topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural and rectal administration. The pharmaceutical compositions may also contain minor

amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and so forth.

Although the preferred routes of administration are systemic, the pharmaceutical composition may be administered topically or transdermally, *e.g.*, as an ointment, cream or gel, orally, rectally, *e.g.*, as a suppository, parenterally, by injection or continuously by infusion, intravaginally, intranasally, intrabronchially, intracranially intra-aurally, or intraocularly.

For topical application, the composition may be incorporated into topically applied vehicles such as a salve or ointment. The carrier for the active ingredient may be either in sprayable or nonsprayable form. Non-sprayable forms can be semi-solid or solid forms comprising a carrier indigenous to topical application and having a dynamic viscosity preferably greater than that of water. Suitable formulations include, but are not limited to, solution, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like. If desired, these may be sterilized or mixed with auxiliary agents, *e.g.*, preservatives, stabilizers, wetting agents, buffers, or salts for influencing osmotic pressure and the like. Preferred vehicles for non-sprayable topical preparations include ointment bases, *e.g.*, polyethylene glycol-1000 (PEG-1000), conventional creams such as HEB cream, gels, as well as petroleum jelly and the like.

Also suitable for topical application are sprayable aerosol preparations wherein the compound, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant. The aerosol preparations can contain solvents, buffers, surfactants, perfumes, and/or antioxidants in addition to the compounds of the invention.

For the preferred topical applications, especially for humans, it is preferred to administer an effective amount of the compound to a target area, *e.g.*, skin surface, mucous membrane, eyes, *etc.* This amount will generally range from about 0.001 mg to about 1 g per application, depending upon the area to be treated, the severity of the symptoms or disease, and the nature of the topical vehicle employed.

The compositions of the invention can also be administered in combination with one or more additional compounds that are used to treat the disease or condition. For treating cancer, the polyamides and derivatives are given in combination with anti-tumor agents, such as mitotic inhibitors, *e.g.*, vinblastine; alkylating agents, *e.g.*,

5 cyclophosphamide; folate inhibitors, *e.g.*, methotrexate, pritrexim or trimetrexate, antimetabolites, *e.g.*, 5-fluorouracil and cytosine arabinoside, intercalating antibiotics, *e.g.*, adriamycin and bleomycin, enzymes or enzyme inhibitors, *e.g.*, asparaginase, topoisomerase inhibitors, *e.g.*, etoposide, or biological response modifiers, *e.g.*, interferon. In fact, pharmaceutical compositions comprising any known cancer

10 therapeutic in combination with the polyamine analogues and derivatives disclosed herein are within the scope of this invention.

Typical single dosages of the compounds of this invention are between about 1 ng and about 10 g/kg body weight. The dose is preferably between about 0.01mg and about 1g/kg body wt. and, most preferably, between about 0.1mg and about 100mg/kg body

15 wt. For topical administration, dosages in the range of about 0.01-20% concentration of the compound, preferably 1-5%, are suggested. A total daily dosage in the range of about 1-500 mg is preferred for oral administration. The foregoing ranges are, however, suggestive, as the number of variables in regard to an individual treatment regime is large, and considerable excursions from these recommended values are expected and may

20 be routinely made by those skilled in the art.

Effective amounts or doses of the compound for treating a disease or condition can be determined using recognized *in vitro* systems or *in vivo* animal models for the particular disease or condition. In the case of cancer, many art-recognized models are known and are representative of a broad spectrum of human tumors. The compositions

25 may be tested for inhibition of tumor cell growth in culture using standard assays with any of a multitude of tumor cell lines of human or nonhuman animal origin. Many of these approaches, including animal models, are described in detail in Geran, R.I. *et al.*, "Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems (Third Edition)", *Canc. Chemother. Reports*, Part 3, 3:1-

30 112.

Administration methods

As noted above, the treatment methods of the invention are directed to the administration of polyamide-containing compositions. The polyamide-containing preparations of the invention may be administered systemically or locally and may be used alone or as components of mixtures. The route of administration may be topical, intravenous, oral, or by use of an implant. For example, polyamides may be administered by means including, but not limited to, topical preparations, intravenous injection or infusion, oral intake, or local administration in the form of intradermal injection or an implant. Additional routes of administration are subcutaneous, intramuscular, or intraperitoneal injections of the polyamides in conventional or convenient forms. Liposomal or lipophilic formulations may also be used when desired. For topical administration, the polyamides may be in standard topical formulations and compositions including lotions, suspensions or pastes. Oral administration of suitable formulations may also be appropriate in those instances where the polyamides may be readily administered to the target cells or tissues via this route.

The dose of polyamides may be optimized by the skilled artisan depending on factors such as, but not limited to, the polyamides chosen, the physical delivery system in which it is carried, the individual subject, and the judgment of the skilled practitioner.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

**EXAMPLE I****Electrophoretic Mobility Shift Assays**

Electrophoretic Mobility Shift Assays were performed to determine whether the addition of various concentrations of polyamides specific for the sequences flanking the TATA box of the HER2/neu promoter could interfere with the DNA binding activity of

the TATA binding protein (TBP). Oligonucleotides corresponding to the HER2/neu TATA box and the adjacent sequences were synthesized. The first oligonucleotide, HERTATA1, has the sequence:

5'-GCTGCTTGAGGAAGTATAAGAATGAAGTTGTGAAG-3' (the TATA box is in bold). The complementary oligonucleotide, HERTATA2, has the sequence:

5'-CTTCACAACTTCATTCTTACTTCCTCAAGCAGC-3'. These complementary 35 base oligonucleotides were 5' end-labeled with  $\gamma$ -<sup>32</sup>P-ATP and T4 polynucleotide kinase and then annealed to give a double-stranded 35 base pair oligonucleotide. This oligonucleotide was then used in electrophoretic mobility shift assays employing 5% nondenaturing polyacrylamide gels (29:1 acrylamide to bisacrylamide) containing 4 mM MgCl<sub>2</sub> and 0.02% (v/v) NP-40 nonionic detergent along with 44 mM Tris-borate, pH 8.3, 1 mM EDTA. The labeled oligo, at a concentration of 0.1 nM, was reacted with 1 nM final concentration of TBP (Promega) in a reaction volume of 20  $\mu$ l, containing 10% glycerol (v/v), 20 mM HEPES-OH, pH 7.9, 25 mM KCl, 0.025% NP-40 (v/v), 100  $\mu$ g/ml bovine serum albumin, 0.5 mM dithiothreitol, 0.8 mM spermidine, 0.1 mM EDTA, 2 mM MgCl<sub>2</sub>.

Various concentrations of the different polyamides, ranging from 0.1 nM to 30 nM, were added to this binding reaction. The reactions were subjected to polyacrylamide gel electrophoresis and the dried gels were subsequently imaged and quantified using a Molecular Dynamics phosphorimager equipped with ImageQuant software. The results are shown in (Figure 4). It is clear that the HER2/neu-specific polyamides (polyamides HER2-1 (Figure 4A), 70 (Figure 4B, squares), and RPR70, of composition ImPyPyPy- $\gamma$ -PyPyPyPy- $\beta$ -RPR, (Figure 4B, x's) significantly decrease TBP binding to the HER2/neu TATA box *in vitro*. A control polyamide 86 (Figure 4B, circles), which is not specific for the HER2/neu TATA box, has little effect on the binding of TBP to the HER2/neu TATA box.

"RPR" indicates the presence of a charged arginine-proline-arginine tail on the polyamide.

## EXAMPLE II

### Inhibition of Transcription *in vitro* In a Cell-Free System

The restriction endonuclease Dra I was used to linearize the plasmid pGEM/HNP, containing the HER2/neu promoter (Ebbinghaus, et al. (1993)), to produce a template for transcription. This template contained 270 base pairs of the HER2/neu promoter as well as 400 base pairs of downstream sequence. Transcription reactions were performed in 20 $\mu$ l reactions containing 100ng of template DNA and 2  $\mu$ l of a HeLa cell nuclear extract in a reaction volume of 25  $\mu$ l as recommended by the supplier (Promega). These reactions were incubated at 30° C for 1 hour in the presence of 10  $\mu$ Ci  $\alpha$ -<sup>32</sup>P-GTP along with unlabeled nucleoside triphosphates at 0.6 mM and 20  $\mu$ M GTP. The labeled transcripts were purified using RNazol as recommended by the supplier (Teltest) and subjected to denaturing polyacrylamide gel electrophoresis on 8% polyacrylamide gels containing 8.3 M urea and 88 mM Tris-borate, pH 8.3, 2 mM EDTA.

The dried gels were imaged and quantitated using a phosphorimager (Molecular Dynamics). The *in vitro* transcription from this HER2/neu promoter template was inhibited by the addition of increasing amounts of polyamide HER2-1 (Figure 5). The addition of 10 nM HER2-1 had no effect, relative to the reaction with no added polyamide, while the addition of 100nM repressed transcription two-fold. As a control, *in vitro* transcription was also performed using the unrelated cytomegalovirus (CMV) promoter as a transcription template. Addition of 10 nM or 100nM polyamide HER2-1 to this template did not significantly decrease the level of transcription.

## EXAMPLE III

### Inhibition of HER2/neu Expression in Cell Culture

A number of breast cancer cell lines were obtained from the American Type Culture Collection and maintained in cell culture. These cell lines included breast cancer cells in which the HER2/neu gene is amplified and greatly overexpressed (SK-BR-3 and ZR 75-1) and breast cancer cells that have normal copy numbers of the HER2/neu gene and express HER2/neu at normal low levels (Hs 578T). Various concentrations of polyamides were added directly into the appropriate cell culture medium supplemented

with 10% (v/v) fetal bovine serum during the growth phase of these cells at 37° C in a 5% CO<sub>2</sub>/air mixture. For the initial experiments, polyamide HER2-1 was added to the medium at various concentrations. A control polyamide (HIV-1) was added in various concentrations to different flasks of cells. Polyamide HIV-1 is similar in structure to 5 HER2-1, but does not specifically recognize the HER2/neu TATA box or its adjacent sequences.

In subsequent experiments, the cell line SK-BR-3 was treated with polyamides for 6 days. In these experiments, polyamide HER2-1 and polyamide 70 in separate experiments were added to the cell culture media for a final concentration of 0.5μM. 10 After 3 days of incubation, fresh media and fresh polyamide were added to the cells. These cells were incubated for an additional 3 days and then harvested for RNA extraction.

Once the cells had grown to confluence in 75 cm<sup>2</sup> culture flasks, the polyamide-treated breast cancer cells were harvested by treating the adherent cells with 2 ml of 15 0.05% trypsin-0.53 mM EDTA (Gibco BRL) to detach the cells from the culture flask. These cells were collected and pelleted in a clinical centrifuge at 5000 rpm (IEC ). The cells were rinsed with cold 1x phosphate buffered saline (PBS) and pelleted in the clinical centrifuge. Total RNA was extracted from the cells using RNazol (Teltest). To a packed cell volume of approximately 100 μl, 1ml of RNazol and 100μl of chloroform were 20 added. This mixture was vortexed for 10 seconds and placed on ice for 10 minutes. The mixture was then spun for 15 minutes in a microfuge at 4° C at 14,000 g. The top layer was removed and total RNA precipitated with one volume of isopropanol. The RNA pellet was washed with 70% ethanol, dried under vacuum, and resuspended in 50-100 μl of RNase-free (DEPC-treated) water containing 1μl of RNasin (40 units).

25 The effects of polyamide addition were subsequently analyzed using reverse transcriptase (RT)-polymerase chain reaction (PCR) as an assay for the relative level of HER2/neu mRNA. These HER2/neu mRNA levels should correlate with the amount of transcription from the HER2/neu promoter, allowing the determination of whether polyamide HER2-1 has any effect on transcription *in vivo*. Using PCR primers specific 30 for the HER2/neu oncogene, the PCR product will correspond to HER2/neu cDNA,

reflecting the relative levels of HER2/neu mRNA. The PCR primers were: (Her2A) 5'-GCTGGCCCGATGTATTGATGGT-3' and (Her2B) 5'-GTTCTCTGCCGTAGGTGTCCCTT-3', and 50 ng of each were used in PCR reactions as described below.

5       The relative amounts of HER2/neu mRNA from the various cells can be determined using reverse transcriptase (RT)-polymerase chain reaction (PCR). After total RNA has been extracted from the polyamide-treated breast cancer cells, as described above, the concentration of total RNA is determined by spectrophotometry (using the optical density at 260 nM) for each different cell type and polyamide concentration. An  
10      equal amount of total RNA (10 ng) is used for each RT-PCR. RT-PCR was carried out using the Reverse Transcription System kit (Promega). Using an oligo dT primer, cDNAs are synthesized from the mRNA templates by the enzyme reverse transcriptase at 42° C for 25 min, as recommended. These cDNAs are then used as templates for PCR.  
15      Using the buffers and Taq polymerase provided in the kit, PCR was carried out at 26 cycles of denaturation at 94° C for 45 seconds, annealing at 60° C for 45 seconds, and extension at 72° C for 2 minutes. Five µCi of the radioactive nucleotide  $\alpha$ -<sup>32</sup>P-dATP is included in the PCR step to produce a radiolabeled PCR product which can be analyzed on an acrylamide gel and visualized by autoradiography. The relative amount of PCR product can be quantitated using a Phosphorimager (Molecular Dynamics). The level of  
20      HER2/neu mRNA from cells which have not been treated with polyamide are the positive control and are given a value of 1.0 and the HER2/neu mRNA levels for the polyamide-treated samples are given a value relative to the value for untreated cells.

The results of these RT-PCR assays are shown in Figure 6. Treatment of the cell lines SK-BR-3 and Hs 578-T with polyamide HER2-1 for 1-2 days resulted in slightly less than two-fold reduction in the relative levels of HER2/neu mRNA. The control polyamide HIV-1 had no apparent effect on the relative levels of HER2/neu mRNA. When SK-BR-3 cells were treated for 6 days with either polyamide HER2-1 or 70, the relative levels of mRNA decreased more significantly than for the 1-2 day treated cells. SK-BR-3 cells showed a 4-fold and 3-fold decrease in the relative levels of HER2/neu  
30      mRNA when treated with polyamide HER2-1 or 70, respectively. These results suggest

that the polyamides can enter the cells and bind to their target nucleotide sequence, thereby interfering with the expression of that gene.

5 All references cited herein are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not.

Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the  
10 invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth as follows in the scope of the appended claims.  
15

What is claimed is:

1. A composition suitable for treating a subject having a condition associated with expression or overexpression of an oncogene, comprising a pharmaceutically acceptable excipient and a transcription-inhibiting amount of at least one polyamide, said polyamide comprising:

at least four complementary pairs of aromatic carboxamide residues, the complementary pairs of aromatic carboxamide residues being selected to correspond to the nucleotide sequence of a dsDNA target;

10 at least two aliphatic amino acid residues chosen from the group consisting of glycine,  $\beta$ -alanine,  $\gamma$ -aminobutyric acid and 5-aminovaleric acid; and  
at least one terminal alkylamino residue.

2. The composition of claim 1 wherein said subject is a human patient.

15 3. The composition of claim 1 wherein said oncogene is a cellular or endogenous oncogene.

20 4. The composition of claim 1 wherein said inhibition of transcription of said oncogene is by modulating the binding to dsDNA of a protein factor selected from the group consisting of ESX, ETS, and TBP.

5. The composition of claim 1 wherein said condition is breast cancer.

25 6. The composition of claim 1 wherein said polyamide has a binding affinity at the target dsDNA sequence of at least  $10^9 \text{ M}^{-1}$  and a selectivity of at least about two.

30 7. The composition of claim 1 wherein the complementary pairs of aromatic carboxamide residues are selected to correspond to the nucleotide sequence of the dsDNA target are chosen from the group consisting of

Im/Py to correspond to the nucleotide pair G/C,  
Py/Im to correspond to the nucleotide pair C/G,  
Py/Py to correspond to the nucleotide pair A/T,  
Py/Py to correspond to the nucleotide pair T/A,  
5 Hp/Py to correspond to the nucleotide pair T/A, and  
Py/Hp to correspond to the nucleotide pair A/T,

where Im is N-methyl imidazole, Py is N-methyl pyrrole, and Hp is 3-hydroxy N-methyl pyrrole.

10 8. The composition of claim 1 wherein at least one aliphatic amino acid residue is  $\beta$ -alanine.

9. The composition of claim 1 wherein said polyamide comprises two  $\beta$ -alanine residues that form a complementary pair of residues corresponding to the nucleotide pair  
15 A/T or T/A.

10. The composition of claim 1 wherein said terminal alkylamino residue is a N,N-dimethylaminopropyl residue.

20 11. The composition of claim 1 wherein at least one Py of a carboxamide pair is replaced by a  $\beta$ -alanine.

12. The composition of claim 1 wherein said polyamide is selected from the group consisting of Her2-1 and RPR70.

25 13. A method of treating a subject having a condition associated with expression or overexpression of an oncogene, comprising administering a composition according to claim 1.

30 14. The method of claim 13 wherein said subject is a human patient.

15. The method of claim 13 wherein said oncogene is a cellular or endogenous oncogene.

5 16. The method of claim 13 wherein said inhibition of transcription of said oncogene is by modulating the binding to dsDNA of a protein factor selected from the group consisting of ESX, ETS, and TBP.

17. The method of claim 13 wherein said condition is breast cancer.

10 18. The method of claim 13 wherein said polyamide has a binding affinity at the target dsDNA sequence of at least  $10^9$  M<sup>-1</sup> and a selectivity of at least about two.

15 19. The method of claim 13 wherein the complementary pairs of aromatic carboxamide residues are selected to correspond to the nucleotide sequence of the dsDNA target are chosen from the group consisting of

Im/Py to correspond to the nucleotide pair G/C,

Py/Im to correspond to the nucleotide pair C/G,

Py/Py to correspond to the nucleotide pair A/T,

Py/Py to correspond to the nucleotide pair T/A,

Hp/Py to correspond to the nucleotide pair T/A, and

Py/Hp to correspond to the nucleotide pair A/T,

where Im is N-methyl imidazole, Py is N-methyl pyrrole and Hp is 3-hydroxy N-methyl pyrrole.

25 20. The method of claim 13 wherein at least one aliphatic amino acid residue is β-alanine.

21. The method of claim 13 wherein said polyamide comprises two  $\beta$ -alanine residues which form a complementary pair of residues corresponding to the nucleotide pair A/T or T/A.

5 22. The method of claim 13 wherein said terminal alkylamino residue is a N,N-dimethylaminopropyl residue.

23. The method of claim 13 wherein at least one Py of a carboxamide pair is replaced by a  $\beta$ -alanine.

10

24. The method of claim 1 wherein said polyamide is selected from the group consisting of polyamides Her2-1, 70, and RPR70.

15

20

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/00, 38/04, 38/08, C12Q 1/68, C12N 5/00, 5/06</b>	A1	(11) International Publication Number: <b>WO 00/15242</b>
		(43) International Publication Date: 23 March 2000 (23.03.00)
<p>(21) International Application Number: PCT/US99/20971</p> <p>(22) International Filing Date: 10 September 1999 (10.09.99)</p> <p>(30) Priority Data: 60/099,906 11 September 1998 (11.09.98) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1200 E. California Boulevard, MS 16-30, Pasadena, CA 91125 (US).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (<i>for US only</i>): DERVAN, Peter, B. [US/US]; California Institute of Technology, 1200 E. California Boulevard, MS 16-30, Pasadena, CA 91125 (US).</p> <p>(74) Agents: CHAMBERS, Daniel, M. et al.; Lyon &amp; Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p>		
<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		

(54) Title: REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES

(57) Abstract

Methods and compositions comprising polyamides capable of binding the minor groove of double-stranded DNA are described for the inhibition or reduction or gene transcription and expression. The polyamides comprise at least four complementary pairs of aromatic carboxamide residues which are selected to specifically contact and/or bind to the nucleotide sequence of a double-stranded DNA target in the promoter region of the target gene. The methods, compositions, and polyamides are disclosed for the inhibition of oncogene transcription and expression as well as the treatment of cancer.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece	<b>ML</b>	Mali	<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>MN</b>	Mongolia	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MR</b>	Mauritania	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MW</b>	Malawi	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MX</b>	Mexico	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>NE</b>	Niger	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NL</b>	Netherlands	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NO</b>	Norway	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NZ</b>	New Zealand	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>PL</b>	Poland		
<b>CM</b>	Cameroon			<b>PT</b>	Portugal		
<b>CN</b>	China	<b>KR</b>	Republic of Korea	<b>RO</b>	Romania		
<b>CU</b>	Cuba	<b>KZ</b>	Kazakhstan	<b>RU</b>	Russian Federation		
<b>CZ</b>	Czech Republic	<b>LC</b>	Saint Lucia	<b>SD</b>	Sudan		
<b>DE</b>	Germany	<b>LI</b>	Liechtenstein	<b>SE</b>	Sweden		
<b>DK</b>	Denmark	<b>LK</b>	Sri Lanka	<b>SG</b>	Singapore		
<b>EE</b>	Estonia	<b>LR</b>	Liberia				

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**REGULATION OF HER/2 neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES**

(Attorney Docket No. 025098-2802)

the specification of which (check one)

is attached hereto.

XX was filed on April 10, 2001 as United States Application 09/807,355 and was amended on        (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
PCT/US99/20971	PCT	September 11, 1998	XX	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date
60/099,906	09/10/98

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

WESLEY B. AMES	Reg. No. 40,893
STEPHEN A. BENT	Reg. No. 29,768
LEI FANG	Reg. No. 44,676
ANDREW EDWARD	Reg. No. 38,473

1008 JUL 86 UNIVIS 800A

Atty. Dkt. No. 025098-2802

GRANSTON	
BERNARD L. KLEINKE	Reg. No. 22,123
STEPHEN E. REITER	Reg. No. 31,192
RICHARD M. SAN PIETRO	Reg. No. 45,071
STACY L. TAYLOR	Reg. No. 34,842
RICHARD J. WARBURG	Reg. No. 32,327
ARTHUR A. WELLMAN JR.	Reg. No. 47,174
MICHAEL A. WHITTAKER	Reg. No. 46,230
BARRY S. WILSON	Reg. No. 39,431

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Michael A. Whittaker  
FOLEY & LARDNER  
Customer No. 23620  
402 W. Broadway, 23<sup>rd</sup> Floor  
San Diego, CA 92107

Telephone: 619-230-6541  
Facsimile: 619-234-3510

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of First inventor

Peter B. Dervan

Residence

1235 St. Albans Rd., San Marino, CA 91108

Citizenship

United States of America

Post Office Address

1235 St. Albans Rd., San Marino, CA 91108

Inventor's signature

P.B.D.

Date

JULY 5, 2002